Hiroshima University group identifies targets for leukemia treatment using CML stem cells

Chronic myelogenous leukemia (CML) might be treated by drugs that inhibit the dipeptide transporter Slc15A2 – a finding based on metabolomic and transciptomic studies by the group of Nakahito NAKAHIRO at Hiroshima University’s A-bomb Radiological Science Institute. Drugs targeting this transporter might help to treat CML patients who have become resistant to tyrosine kinase inhibitors. A physician-led clinical study is in preparation.

Communication at 12th Translational Workshop for Molecular Target Therapy of Cancer, January 17, 2017

Hiroshima University group identifies targets for leukemia treatment using CML stem cells
Scroll to top